CAR T-cell therapy in autoimmune diseases

Georg Schett(Friedrich-Alexander-Universität Erlangen-Nürnberg), Georg Schett(Friedrich-Alexander-Universität Erlangen-Nürnberg), Andréas Mackensen(Universitätsklinikum Erlangen), Dimitrios Mougiakakos(Otto-von-Guericke-Universität Magdeburg), Dimitrios Mougiakakos(Otto-von-Guericke-Universität Magdeburg)

The Lancet

September 22, 2023

10.1016/s0140-6736(23)01126-1

Cited by 360

Abstract

Related Papers

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

David L. Porter, Bruce L. Levine, Michael Kalos et al.|New England Journal of Medicine|2011|3.5k

Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis

Jonathan Edwards, L Szczepański, Jacek Szechiński et al.|New England Journal of Medicine|2004|2.6k

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Marco L. Davila, Isabelle Rivière, Xiuyan Wang et al.|Science Translational Medicine|2014|2.5k

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

Emily C. Baechler, Franak Batliwalla, George Karypis et al.|Proceedings of the National Academy of Sciences|2003|2.2k

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Richard Furie, Michelle Petri, Omid Zamani et al.|Arthritis & Rheumatism|2011|1.6k